Observation On The Curative Effect Of Diloulifeiyin In The Treatment Of Chronic Obstructive Pulmonary Disease In Acute Exacerbation Of Phlegm-heat Stagnation Lung Syndrome

Objective:To observe the clinical efficacy and safety of Di Lou Li Fei decoction in the treatment of acute exacerbations of chronic obstructive pulmonary disease（AECOPD）with phlegm heat stagnation lung syndrome,so as to provide the clinical basis for the clinical application and further promotion of this prescription.Methods:90 AECOPD patients with phlegm heat stagnation lung syndrome were randomly divided into three groups:A,B and C,30 cases in each group.Group A was treated by western medicine,group B was treated by western medicine and diluolifeiyin orally,group C was treated by routine treatment and Tanreqing injection.The course of treatment was 10 days.The clinical effect,TCM syndrome score,WBC,N%,CRP,Pa CO₂and Pa O₂were compared before and after treatment.SPSS 23.0 was used for data analysis.Result:1.Clinical efficacy:the total effective rate of group A,B and C was 76.92%,96.43%and 93.10%respectively.The difference between the two groups was statistically significant(P_AB=0.006,P_AC=0.043<0.05),P_BC=0.496>0.05,no statistical significance.We think that the clinical efficacy of group B and C was equivalent,and better than that of group A.2.TCM syndrome score:2.After treatment,the TCM syndrome score of the three groups was significantly improved compared with that before treatment（P<0.05）.After treatment,there was no statistically significant difference between the B group and the C group（P>0.05）,but group B and group C was better than group A,and the difference was statistically significant（P<0.05）.Therefore,in terms of improving TCM syndrome scores,group B and Group C had similar efficacy,both of which were better than group A.3.Inflammation index:WBC,N%and CRP decreased in three groups after treatment（P<0.05）.After treatment,the difference between the two groups was statistically significant,indicating that group B was better than group C and better than group A in reducing inflammation index.4.In blood gas analysis,Pa CO₂and Pa O₂:Pa CO₂and Pa O₂could be effectively improved after treatment in three groups（P<0.05）.After treatment,there was a significant difference between the two groups（P<0.05）,indicating that B group was better than C group in improving carbon dioxide retention and hypoxia,and was better than A group.5.Lung function:after treatment,FEV₁/FVC and FEV₁in the three groups were significantly improved before treatment（P<0.05）.After treatment,there was no statistically significant difference between the B group and the C group（P>0.05）,but group B and group C was better than group A,and the difference was statistically significant（P<0.05）.This indicates that in terms of improving lung function,the efficacy of group B and Group C is similar,both of which are better than group A.6.Safety evaluation:group A and group B had no obvious adverse reactions.Conclusion:This study indicates that the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease with phlegm-heat stagnation syndrome by di Lou Li Fei decoction can effectively relieve symptoms and signs,reduce airway inflammation,improve lung ventilation and lung function,with significant clinical efficacy and no obvious adverse reactions.